Global InformationLisocabtagene maraleucel information
| Gene therapy | |
|---|---|
| Target gene | CD19 |
| Clinical data | |
| Trade names | Breyanzi |
| Other names | JCAR017, LM |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621017 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat B-cell lymphoma.[3][6]
Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system.[6] The most common side effects include decreases in neutrophils (a type of white blood cell that fights infections), in red blood cells or in blood platelets (components that help the blood to clot), as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure) and tiredness.[4]
Lisocabtagene maraleucel, a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, is the third gene therapy approved by the US Food and Drug Administration (FDA) for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL).[6] Lisocabtagene maraleucel was approved for medical use in the United States in February 2021.[3][6]
- ^ "Summary Basis of Decision - Breyanzi". Health Canada. 16 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
- ^ "Breyanzi- lisocabtagene maraleucel kit". DailyMed. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
- ^ a b c Cite error: The named reference
FDA Breyanziwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Breyanzi EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Breyanzi PIwas invoked but never defined (see the help page). - ^ a b c d "FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 5 February 2021. Archived from the original on 5 March 2022. Retrieved 5 February 2021.
This article incorporates text from this source, which is in the public domain.
